This content is in French.
Benzbromarone, a new therapy to combat cystic fibrosis
27 juin 2024
Cystic fibrosis is an autosomal recessive genetic disease. It affects multiple organs, but the most serious consequences are in the lungs. Around 90% of patients succumb to the progression of this lung disease.
Experimental studies have demonstrated the role of the TMEM16A antibody in the production and secretion of mucus.
Benzbromarone, a uricosuric agent used to treat chronic gout, has been shown to inhibit TMEM16A activity in animal models, suggesting potential therapeutic benefits by reducing mucus production and the severity of this disease.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Friedrich F, Petry LM, Garcia LCE, Pieta MP, Meneses ADS, Bittencourt LB, Xavier LF, Antunes MOB, Grun LK, Lumertz M, Kunzelmann K, Pinto LA. Benzbromarone as adjuvant therapy for cystic fibrosis lung disease: a pilot clinical trial. J Bras Pneumol. 2024
View the source
